Thursday - April 25, 2024

Acurx Pharmaceuticals’ Phase 2b Results For Ibezapolstat Bests Standard Of Care Vancomycin To Treat C. Difficile ($ACXP)

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) stock may present an investment opportunity that is too good to ignore. That assessment is more than warranted; it’s justified, based on results from its Phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, … Continue reading